Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 229 publications

Cholangiocarcinoma - Morphology, Immunohistochemistry, and Genetics.

Cholangiocarcinoma - Morphology, Immunohistochemistry, and Genetics.

Journal: Ceskoslovenska patologie
Published: October 16, 2025

Rare gliomas: standard treatment approaches and new target therapies.

Rare gliomas: standard treatment approaches and new target therapies.

Journal: Current opinion in neurology
Published: September 24, 2025

Identifying Drug Combination Strategies for ZMYM2: FGFR1 Fusion Positive Leukemia.

Identifying Drug Combination Strategies for ZMYM2: FGFR1 Fusion Positive Leukemia.

Journal: Precision oncogenomics
Published: August 29, 2025

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.

Journal: NEJM evidence
Published: August 26, 2025

Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation.

Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation.

Journal: The oncologist
Published: August 18, 2025

Pemigatinib in the Real-World Management of Cholangiocarcinoma Through a Canadian Patient Support Program.

Pemigatinib in the Real-World Management of Cholangiocarcinoma Through a Canadian Patient Support Program.

Journal: Current oncology (Toronto, Ont.)
Published: July 04, 2025

Pemigatinib therapy in myeloid/lymphoid neoplasm with FGFR1 rearrangement manifesting as aggressive B-cell lymphoma.

Pemigatinib therapy in myeloid/lymphoid neoplasm with FGFR1 rearrangement manifesting as aggressive B-cell lymphoma.

Journal: Journal of clinical and experimental hematopathology : JCEH
Published: June 29, 2025

Sequential Fibroblast Growth Factor Receptor Inhibition in Intrahepatic Cholangiocarcinoma: Navigating an Evolving Landscape of Resistance and Opportunity-A Case Report and Current Opinion.

Sequential Fibroblast Growth Factor Receptor Inhibition in Intrahepatic Cholangiocarcinoma: Navigating an Evolving Landscape of Resistance and Opportunity-A Case Report and Current Opinion.

Journal: Oncology and therapy
Published: June 16, 2025

Reply to Letter in reference to "Neoadjuvant pemigatinib as a bridge to living donor liver transplantation for intrahepatic cholangiocarcinoma with FGFR2 rearrangement".

Reply to Letter in reference to "Neoadjuvant pemigatinib as a bridge to living donor liver transplantation for intrahepatic cholangiocarcinoma with FGFR2 rearrangement".

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Published: June 03, 2025

Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review.

Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review.

Journal: Oncology and therapy
Published: May 23, 2025

FGFR1 Inhibition by Pemigatinib Enhances Radiosensitivity in Glioblastoma Stem Cells Through S100A4 Downregulation.

FGFR1 Inhibition by Pemigatinib Enhances Radiosensitivity in Glioblastoma Stem Cells Through S100A4 Downregulation.

Journal: Cells
Published: May 12, 2025

Calcinosis Cutis With Selective Fibroblast Growth Factor Receptor Inhibitors: A Case Report and Review of Literature.

Calcinosis Cutis With Selective Fibroblast Growth Factor Receptor Inhibitors: A Case Report and Review of Literature.

Journal: Cureus
Published: May 08, 2025
Showing 1-12 of 229

Last Updated: 10/31/2025